Virginia · 2026 Regular Session · Bill
HB 516: Health insurance; coverage for non-opioid prescription drugs.
In committee Official data
- Introduced
- In committee
- Passed one chamber
- Passed both chambers
- Enacted
Last official action: ·Record last updated:
Plain-language summary
HB 516 is a bill introduced in the Virginia House on January 13, 2026. According to its official title, it concerns: Health insurance; coverage for non-opioid prescription drugs. Primary sponsor: Marty Martinez (Democratic). Most recent recorded action (February 18, 2026): Left in Labor and Commerce.
Generated automatically from the official title, sponsor list, and status record only. It does not characterize the bill’s purpose or effects. How summaries are written
Official summary
Abstract published by the legislature (via Open States). Text as published by the legislature; reproduced verbatim.
Health insurance; coverage for non-opioid prescription drugs. Prohibits a health insurance carrier from imposing any cost-sharing, prior authorization, step therapy, or other limitation on coverage of a covered non-opioid drug approved by the U.S. Food and Drug Administration for the treatment or management of pain that is more restrictive or less favorable to the enrollee relative to a covered opioid drug approved by the U.S. Food and Drug Administration for the treatment or management of pain.
Sponsors
Sponsors by party (alphabetical): Democratic 1
| Name | Role | Party | Chamber | District |
|---|---|---|---|---|
| Marty Martinez | Primary sponsor | Democratic | House | 29 |
“Support” is shown only as formal sponsorship recorded by the legislature. Roll-call votes are available on the official bill page.
Recent official actions
- Left in Labor and Commerce
- Subcommittee recommends laying on the table (5-Y 4-N)
- Fiscal Impact Statement from Department of Planning and Budget (HB516)
- Assigned HCL sub: Subcommittee #1
- Referred to Committee on Labor and Commerce
- Prefiled and ordered printed; Offered 01-14-2026 26101109D